COMPANY

Carna Biosciences

Profile checked Oct 10, 2026

Keywords: B-cell Malignancy Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Waldenstrom Macroglobulinemia Mantle Cell Lymphoma Marginal Zone Lymphoma Follicular Lymphoma Non-Hodgkin Lymphoma Docirbrutinib

1Trials (company is sponsor)

Timeline

Aug 1, 2023 Trial start Phase 1: AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma source ↗

Upcoming milestones

2027-09 (ESTIMATED) · Phase 1 · AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma · NCT05602363

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 1

Record	Title	Phase	Status	Start	Primary completion
NCT05602363	AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma	Phase 1	Recruiting	Aug 1, 2023	2027-09 (estimated)